

=> d his

(FILE 'HOME' ENTERED AT 10:57:36 ON 20 NOV 2007)

FILE 'REGISTRY' ENTERED AT 10:57:44 ON 20 NOV 2007


L1 SCREEN 1839
L2 SCREEN 1840
L3 STRUCTURE UPLOADED
L4 835823 S SC4/ES
L5 5 S (L3 NOT L2) SAM SUB=L4
L6 159 S (L3 NOT L2) SSS FULL SUB=L4

FILE 'CAPLUS' ENTERED AT 10:59:53 ON 20 NOV 2007

L7 21 S L6
L8 2 S US2001-537697/APPS
L9 1 S L7 AND L8
L10 20 S L7 NOT L8

FILE 'REGISTRY' ENTERED AT 11:00:22 ON 20 NOV 2007

=> d l3
L3 HAS NO ANSWERS
L3 STR



Structure attributes must be viewed using STN Express query preparation.


=> d 19 bib abs

L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:515662 CAPLUS
DN 141:47386
TI Ureidothiophene compound NF- κ B inhibitor for therapeutic use
IN Callahan, James Frances; Li, Yue Hu
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004053087	A2	20040624	WO 2003-US38970	20031205
	WO 2004053087	A3	20040910		
	W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, EG, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, VN, YU, ZA				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003300832	A1	20040630	AU 2003-300832	20031205
	EP 1569924	A2	20050907	EP 2003-812858	20031205
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006510676	T	20060330	JP 2004-559435	20031205
	US 2006116419	A1	20060601	US 2005-537697	20050606 <--
PRAI	US 2002-431496P	P	20021206		
	WO 2003-US38970	W	20031205		
AB	The invention provides 5-(4-fluorophenyl)-2-ureidothiophene-3-carboxylic acid amide (preparation described) and methods for treating diseases related to the inhibition of IKK- β phosphorylation of I κ .				

> d 110 tot bib abs hitstr

ANSWER 1 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
 2007:1060852 CAPLUS Full-text
 DN 147:378396
 TI nf-kb activation inhibitors for treating muscular wasting diseases
 IN Guttridge, Denis C.; Baldwin, Albert S.
 PA Therapeutics, Inc., USA
 SO PCT Int. Appl., 64pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 PAN.CNT 1




PATENT NO. KIND DATE APPLICATION NO. DATE
 PI WO 2007106884 A2 2007-08-20 US 2007-0864057 200709315
 W, AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
 KP, KR, KZ, LA, LC, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN,
 MM, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
 RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, VN, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BE,
 BJ, CF, CG, CI, CM, CA, GN, GQ, OM, ML, MR, NE, SN, TD, TG, BW,
 GH, KM, KE, LS, MW, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM

US 2007252513 A1 2007-07-17 US 2007-686623 20070315

PRAI US 2006-722427P P 2006-0315
 AB Methods for treating muscular wasting diseases such as Duchenne muscular dystrophy are disclosed. Specifically, the methods include administering to a subject in need of treatment a nuclear factor kappa B (NF-kB) activation inhibitor capable of blocking the activation of NF-kB. Administration of peptides comprised of a Nuclear Factor Essential (NEMO) binding domain to a mouse model of Duchenne muscular dystrophy significantly increased diaphragm contractions.

IT 354810-86-9 507475-17-4
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nf-kb activation inhibitors for treating muscular wasting diseases)

RN 354810-86-9 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)




RN 507475-17-4 CAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 3 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2007:76699 CAPLUS Full-text
 DN 146:115045
 TI Treating type 2 diabetes or metabolic syndrome with an interleukin 1 β inhibitor or an interleukin 1 β synthesis or release inhibitor
 PA Novo Nordisk A/S, Den.
 SO Dan. Pat. Appl., 16pp.
 CODEN: DAXXBG
 DT Patent
 LA English
 PAN.CNT 1


PATENT NO. KIND DATE APPLICATION NO. DATE
 PI DK 2006000313 A 20060313 DK 2006-313 20060303
 PRAI DK 2006-313 20060303
 AB The invention describes a method for treating type 2 diabetes or metabolic syndrome with a compound that inhibits (a) 1L-1 β , (b) the synthesis of 1L-1 β , or (c) the release of 1L-1 β .
 IT 354810-80-3 354810-93-6 354810-86-9
 354810-88-1 354810-95-6 354811-01-1
 354811-04-4 354811-06-6 354811-07-7
 354811-08-8 354811-09-5 354811-10-2
 354811-14-6 354811-15-7 354811-15-1
 354811-27-1 354811-28-2 354811-39-3
 354811-30-6 354811-31-7 354811-32-8
 354811-33-9 354811-34-0 354811-35-1
 354811-36-2 354811-37-7 354811-38-4
 354811-39-5 354811-40-6 354811-41-9
 354811-42-0 354811-49-6 354811-49-7
 354811-50-0 354811-52-2 354811-54-4
 354811-56-6 354811-59-8 354811-59-9
 354811-60-2 354811-66-6 354811-67-5
 354811-68-0 354811-92-8 354811-03-9
 918475-53-3
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (interleukin 1 β inhibitor or interleukin 1 β synthesis or release inhibitor for treatment of type 2 diabetes or metabolic syndrome)

RN 354810-80-3 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-phenyl- (CA INDEX NAME)




RN 354810-83-6 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(3-chlorophenyl)- (CA INDEX NAME)


INDEX NAME)




RN 354810-86-9 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-chlorophenyl)- (CA INDEX NAME)




RN 354810-88-1 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-chlorophenyl)- (CA INDEX NAME)




RN 354810-95-0 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)- (CA INDEX NAME)




RN 354811-01-1 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(3-hydroxyphenyl)- (CA INDEX NAME)




RN 354811-04-4 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(2-chlorophenyl)- (CA INDEX NAME)




RN 354811-06-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(2-methoxyphenyl)- (CA INDEX NAME)




RN 354811-07-7 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[2-(2-dimethylamino)ethoxy]phenyl)- (CA INDEX NAME)




RN 354811-08-8 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-(2-dimethylamino)ethoxy]phenyl)- (CA INDEX NAME)




RN 354811-19-1 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[3-(3-dimethylamino)propoxy]phenyl)- (CA INDEX NAME)




RN 354811-27-1 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[2-(3-dimethylamino)propoxy]phenyl)- (CA INDEX NAME)




RN 354811-28-2 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-chlorophenyl)-4-methyl- (CA INDEX NAME)




RN 354811-29-3 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-(4-methylphenyl)- (CA INDEX NAME)




RN 354811-09-9 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)- (CA INDEX NAME)




RN 354811-10-2 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-phenyl- (CA INDEX NAME)




RN 354811-14-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-(dimethylamino)propoxy]phenyl)- (CA INDEX NAME)




RN 354811-15-7 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[3-(2-dimethylamino)ethoxy]phenyl)- (CA INDEX NAME)




RN 354811-30-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-ethyl-5-phenyl- (CA INDEX NAME)




RN 354811-31-7 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-4-methyl- (CA INDEX NAME)




RN 354811-32-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-4-methyl- (CA INDEX NAME)




RN 354811-33-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-fluorophenyl)-4-methyl- (CA INDEX NAME)




RN 354811-34-0 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)-4-methyl- (CA INDEX NAME)




RN 354811-35-1 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-5-(3-chloro-4-methoxyphenyl)-4-methyl- (CA INDEX NAME)




RN 354811-36-2 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-4-methyl- (CA INDEX NAME)





RN 354811-37-3 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 354811-38-4 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxy-3-methylphenyl)-4-methyl- (CA INDEX NAME)




RN 354811-39-5 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-5-(3,5-dimethoxyphenyl)-4-methyl- (CA INDEX NAME)




RN 354811-41-9 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-[4-(1-methylethyl)phenyl]- (CA INDEX NAME)



RN 354811-42-0 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 354811-48-6 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-5-(3,4-dichlorophenyl)-4-methyl- (CA INDEX NAME)




RN 354811-49-7 CAPLUS


CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-5-(4-cyanophenyl)-4-methyl- (CA INDEX NAME)




RN 354811-50-0 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)-4-methyl- (CA INDEX NAME)




RN 354811-52-2 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-5-(4-(diethylamino)ethoxyphenyl)-4-methyl- (CA INDEX NAME)




RN 354811-54-4 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-5-phenyl-4-(trifluoromethyl)- (CA INDEX NAME)




RN 354811-56-6 CAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-phenyl- (CA INDEX NAME)




RN 354811-58-8 CAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-cyanophenyl)- (CA INDEX NAME)




RN 354811-59-9 CAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 354811-60-2 CAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2,4-difluorophenyl)- (CA INDEX NAME)



RN 354811-83-9 CAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(2-diethylamino)ethoxyphenyl]- (CA INDEX NAME)




RN 918475-53-3 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-(1,1-dimethyl ethyl)phenyl]- (CA INDEX NAME)




ANSWER 4 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2007:56134 CAPLUS Full-text
 DN 147:163639
 TI Utility of exhaled nitric oxide as a noninvasive biomarker of lung inflammation in a disease model
 AU Birrell, M. A.; McCluskie, K.; Hardaker, E.; Knowles, R.; Belvisi, M. G.
 CS Respiratory Pharmacology, Imperial College London, Faculty of Medicine, National Heart and Lung Institute, London, UK
 SO European Respiratory Journal (2006), 28(6), 1236-1244
 CODEN: ERJODI; ISSN: 0903-1936
 PB European Respiratory Society
 DT Journal
 LA English
 AB There is a great deal of interest in developing less invasive markers for monitoring airway inflammation and the effect of possible novel anti-inflammatory therapies that may take time to impact on disease pathol. Exhaled nitric oxide (eNO) has been shown to be a reproducible, noninvasive indicator of the inflammatory status of the airway in the clinic. The aim of the present study was to determine the usefulness of measuring eNO as a marker


RN 354811-66-8 CAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)- (CA INDEX NAME)



RN 354811-67-9 CAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-chlorophenyl)- (CA INDEX NAME)



RN 354811-68-0 CAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 354811-82-8 CAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(2-dimethylamino)ethoxyphenyl]- (CA INDEX NAME)



10537697 16 of 87
 of the anti-inflammatory impact of glucocorticoid and an inhibitor of kB kinase-2 (IKK-2) inhibitor 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide (TPCA-1), in a pre-clin. model of airway inflammation. Rats were given vehicle, budesonide or TPCA-1 prior to exposure to lipopolysaccharide, previously shown to induce an increase in eNO and airway neutrophilia/eosinophilia. Comparison of the effect of the two compds. on inflammatory components demonstrated a significant correlation between the impact on eNO and inflammatory cell burden in the airway. The current study demonstrates the usefulness of profiling potential disease-modifying therapies on exhaled nitric oxide levels and the way in which an effect on this noninvasive biomarker relates to effects on pathol. parameters such as lung cellularity. Information from studies such as the current one would suggest that the measurement of exhaled nitric oxide has potential for monitoring inflammatory status in lung tissue.

IT 507475-17-4, TPCA-1
 RL: BSV (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (exhaled nitric oxide as noninvasive biomarker of airway inflammation in a rat model)

RN 507475-17-4 CAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)



RE CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 5 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:1157366 CAPLUS Full-text
 DN 145:4656677

TI BAFF and APRIL neutralization-based methods for treating disease by regulating chronic lymphocytic leukemia (CLL) cell survival
 IN Kipps, Thomas J.; Endo, Tomoyuki; Nishio, Mitsufumi
 PA The Regents of the University of California, USA
 SO PCT Int. Appl., 52pp.
 CODEN: PIXAD2

DT Patent
 LA English
 FAN. CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE

 PI WO 2006116366 A2 20061102 WO 2006-US15572 20060424
 WO 2006116366 A3 20070405
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TZ, UA, UG, US, UZ, VC.

VN, YU, ZA, ZM, ZH
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GM, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AP, EA, BP, OA

PRAI US 2005-674239P 6050422

AB The invention discloses methods for regulating apoptosis in cell comprising contacting the cell with an agent capable of neutralizing BAFF or APRIL. The invention also discloses a method for treating leukemia. The invention further discloses a method for detecting inhibitors of CLT.


IT 507475-17-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(BAFF and APRIL neutralization-based methods for treating disease by regulating chronic lymphocytic leukemia cell survival)

RN 507475-17-4 CAPLUS

CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)



L10 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:551763 CAPLUS Full-text
DN 145:180624

TI I_KB kinase-2-independent and -dependent inflammation in airway disease models: relevance of I_KK-2 inhibition to the clinic

AU Birrell, Mark A.; Wong, Sissie; Hardaker, Elizabeth L.; Catley, Matthew C.; McCluskie, Kerryn; Collins, Michael; Haj-Yahia, Saleem; Belvisi, Maria G.

CS Respiratory Pharmacology Group, Airway Diseases Department, Faculty of Medicine, National Heart and Lung Institute, Imperial College, London, UK

SO Molecular Pharmacology (2006), 69(6), 1791-1800

CODEN: MOPMA3; ISSN: 0026-895X

PB American Society for Pharmacology and Experimental Therapeutics

DT Journal

LA English

AB Nuclear factor κ B (NF- κ B) is a transcription factor believed to be central in the expression of numerous inflammatory genes and the pathogenesis of many respiratory diseases. We have previously demonstrated increased NF- κ B pathway activation in a steroid-sensitive animal model of lipopolysaccharide (LPS)-driven airway inflammation. It is noteworthy that this phenomenon was not observed in a steroid-insensitive model of elastase-induced inflammation in the rat. The aim of this study was to gather further evidence to suggest that these similar profiles of neutrophilic inflammation can be NF- κ B-dependent or -independent by determining the impact of an I_KB kinase-2 (IKK-2) inhibitor, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophene carboxamide (TPCA-1). In the LPS model, TPCA-1 blocked the increase in NF- κ B DNA binding, a marker

AB High-throughput screening is routinely employed as a method for the identification of novel hit structures. Large nos. of active compds. are typically procured in this way and must undergo a rigorous validation process. This process is described in detail for a collection of screening hits identified as inhibitors of I_KB kinase- β (IKK β), a key regulatory enzyme in the nuclear factor- κ B (NF- κ B) pathway. From these studies, a promising hit series was selected. Subsequent lead generation activities included the development of a pharmacophore hypothesis and structure-activity relationship (SAR) for the hit series. This led to the exploration of related scaffolds offering addnl. opportunities, and the various structural classes were comparatively evaluated for enzymatic inhibition, selectivity, and drug-like properties. A novel lead series of thienopyridines was thereby established, and this series advanced into lead optimization for further development.

IT 719620-78-1 CAPLUS


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(thienopyridine class of inhibitors of I_KB kinase- β :

hit-to-lead strategies)

RN 719620-78-1 CAPLUS

CN 2-Thiophene carboxamide, 3-[(methylamino)carbonyl]amino]-5-phenyl- (CA INDEX NAME)



IT 354810-80-3


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(thienopyridine class of inhibitors of I_KB kinase- β :

hit-to-lead strategies)

RN 354810-80-3 CAPLUS

CN 2-Thiophene carboxamide, 3-[(aminocarbonyl)amino]-5-phenyl- (CA INDEX NAME)



RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:777848 CAPLUS Full-text

DN 145:262418

TI A Critical Assessment of Docking Programs and Scoring Functions

of NF- κ B pathway activation. This inhibition was associated with a reduction in inflammatory mediator release (tumor necrosis factor α (TNF- α)/interleukin-1 β (IL-1 β)/matrix metalloproteinase-9 (MMP-9)) and lung inflammatory cell burden (neutrophilia/eosinophilia). These data were paralleled with a steroid and in human cell based assays. In the elastase-driven inflammation model, in which our group has previously failed to measure an increase in NF- κ B DNA binding, neither TPCA-1 nor the steroid, affected mediator release (IL-1 β /MMP-9) or cellular burden (neutrophilia/lymphomononuclear cells). This is the first study to examine the effect of an IKK-2 inhibitor in well validated models that mimic aspects of the inflammatory lesion evident in diseases such as COPD. In conclusion, we have demonstrated that animal models with similar profiles of airway inflammation can be IKK-2 inhibitor/steroid-sensitive or -insensitive. If both profiles of inflammation exist in the clinic, then this finding is extremely exciting and may lead to greater understanding of disease pathol. and the discovery of novel anti-inflammatory targets.

IT 507475-17-4P


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(IKB kinase-2-independent and -dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic)

RN 507475-17-4 CAPLUS

CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)



RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:357148 CAPLUS Full-text

DN 145:39831

TI Evolution of the Thienopyridine Class of Inhibitors of I_KBAU Kinase- β ; Part I: Hit-to-Lead Strategies

Morwick, Tina; Berry, Angela; Brickwood, Janice; Cardozo, Mario; Catron, Katrina; DeTuri, Molly; Emeigh, Jonathan; Homon, Carol; Hrapchak, Matt; Jacob, Stephen; Jakes, Scott; Kaplita, Paul; Kelly, Terence A.; Keizak, John; Liuzzi, Michel; Magolda, Ronald; Mao, Can; Marshall, Daniel; McNeil, Daniel; Prokopowicz, Anthony, III; Sarko, Christopher; Scouten, Erika; Sledziona, Cynthia; Sun, Sanxing; Watrous, Jane; Wu, Jiang Ping; Cywin, Charles L.

CS Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, 06801-0368, USA

SO Journal of Medicinal Chemistry (2006), 49(10), 2898-2908

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

OS CASREACT 145:39831

AU Warren, Gregory L.; Andrews, C. Webster; Capelli, Anna-Maria; Clarke, Brian; LaLonde, Judith; Lambert, Millard H.; Lindvall, Mikla; Nevins, Neya; Semus, Simon F.; Senger, Stefan; Tedesco, Giovanna; Wall, Ian D.; Woolven, James M.; Peisjoh, Catherine E.; Head, Martha S.

CS GlaxoSmithKline Pharmaceuticals, Collegeville, PA, 19426, USA

SO Journal of Medicinal Chemistry (2006), 49(20), 5912-5931

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

AB Docking is a computational technique that samples conformations of small mols. in protein binding sites; scoring functions are used to assess which of these conformations best complements the protein binding site. An evaluation of 10 docking programs and 37 scoring functions was conducted against eight proteins of seven protein types for three tasks: binding mode prediction, virtual screening for lead identification, and rank-ordering by affinity for lead optimization. All of the docking programs were able to generate ligand conformations similar to crystallog. determined protein/ligand complex structures for at least one of the targets. However, scoring functions were less successful at distinguishing the crystallog. conformation from the set of docked poses. Docking programs identified active compds. from a pharmaceutically relevant pool of decoy compds.; however, no single program performed well for all of the targets. For prediction of compound affinity, none of the docking programs or scoring functions made a useful prediction of ligand binding affinity.


IT 507475-23-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(critical assessment of docking programs and scoring functions)

RN 507475-23-2 CAPLUS

CN 3-Thiophene carboxamide, 5-(4-fluorophenyl)-N-methyl-2-[(methylamino)carbonyl]amino- (CA INDEX NAME)



RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:638873 CAPLUS Full-text

DN 143:153276

TI Preparation of substituted heterocycles, particularly ureidothiophenes, as

IN Ashwell, Susan; Gero, Thomas; Ioannidis, Stephanos; Janetka, James; Lyne, Paul; Su, Mai; Toader, Dorin; Yu, Dingwei; Yu, Yan

PA Astrazeneca AB, Swed.; Astrazeneca UK Limited

SO PCT Int. Appl., 148 pp.

CODEN: PIIXD2

DT Patent

LA English


L10 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:777848 CAPLUS Full-text


DN 145:262418

TI A Critical Assessment of Docking Programs and Scoring Functions


FAN.CNT 1	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005066163	A2	20050721	WO 2004-GB5400	20041224
	WO 2005066163	A3	20050901		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
AU 2004312193	A1	20050721	AU 2004-312193	20041224	
CA 2552050	A1	20050721	CA 2004-2552050	20041224	
EP 1732920	A2	20061220	EP 2004-806196	20041224	
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1922172	A	20070228	CN 2004-80042170	20041224	
BR 2004018351	A	20070504	BR 2004-18351	20041224	
JP 2007517843	T	20070705	JP 2006-548370	20041224	
US 2007010556	A1	20070111	US 2006-596930	20060629	
NS 2006003449	A	20060727	NO 2006-3449	20060726	
IN 2006MN00910	A	2007013	IN 2006-MN910	20060731	
PRAI US 2004-5343110P	P	20040105			
US 2004-553305P	P	20040115			
WO 2004-GB5400	W	20040224			
OS MARPAT 143:153276					
GI					




AB Title compds. I (wherein X = NH, S, O; Y = CH, N; R1 = CN, (un)substituted alk(en)yl, alkoxy, aryl, etc.; R2, R3 = independently CONH2 and derivs., SO2NH2 and derivs., NHCONH4; R4 = H, OH, benzyl, etc.; and their pharmaceutically acceptable salts; provided that when X = S; Y = CH; R2 = CONH2 and derivs.; and R3 = NHCONH4; then R1 cannot be hydroxyphenyl or alkoxyphenyl; with the exception of certain compds.) were prepared as




RN 860353-67-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-(2-aminoethyl)-5-phenyl- (CA INDEX NAME)




RN 860353-74-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-[2-(dimethylamino)ethyl]-5-phenyl- (CA INDEX NAME)



RN 860353-89-5 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-(2-hydroxyethyl)-5-phenyl- (CA INDEX NAME)




checkpoint kinase 1 inhibitors for treating cancer. For example, a 7-step synthesis of ureidothiophene salt II•HCl, starting from phenylacetalddehyde and cyanomethyl acetate, is given. I had IC50 or EC50 ≤ 100 μM in one or both, checkpoint kinase 1 and abrogation assays.					
IT 860351-93-5, (R)-2-Amino-3-[(5-phenyl-3-ureidothien-2-yl)carbonyl]aminopropionic acid methyl ester 860351-94-6, 5-Phenyl-3-ureidothiophene-2-carboxylic acid ((2R)-2-amino-3-hydroxypropyl)amide 860351-95-7P, 5-Phenyl-3-ureidothiophene-3-carboxylic acid (2-aminoethyl)amide 860351-96-8P, 5-Phenyl-2-ureidothiophene-3-carboxylic acid (2-hydroxyethyl)amide					
RN 860351-93-5 CAPLUS					
CN D-Alanine, 3-[(3-[(aminocarbonyl)amino]-5-phenyl-2-thienyl]carbonyl)amino]-, methyl ester (CA INDEX NAME)					
Absolute stereochemistry.					



RN 860351-94-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-N-[(2R)-2-amino-3-hydroxypropyl]-5-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 860351-95-7 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-N-[(2S)-2-amino-3-hydroxypropyl]-5-phenyl- (CA INDEX NAME)

Absolute stereochemistry.

AN	2005:158658 CAPLUS Full-text	DN	142:261391	TI	Preparation of thiophene compounds as CHK1 inhibitors
IN	Ashwell, Susan; Gero, Thomas; Ioannidis, Stephanos; Janetka, James; Lyne, Paul; Oza, Vibha; Springer, Stephanie; Su, Mei; Yu, Dingwei	PA	Astrazeneca AB, Lund; AstraZeneca UK Limited	SO	PCT Int. Appl., 97 pp.
	CODEN: PIXKD2	DT	Patent	LA	English
FAN.CNT 1	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005016909	A1	20050224	WO 2004-GB3473	20040812
W:	AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MO, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UC, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UC, UC, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
AU 20042615140	A1	20050224	AU 2004-265140	20040812	
CA 2535652	A1	20050224	CA 2004-2535652	20040812	
EP 1660474	A1	20060531	EP 2004-768043	20040812	
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HG, PL, SK, HR				
BR 2004013585	A	20061017	BR 2004-13585	20040812	
CN 1867557	A	20061122	CN 2004-80030364	20040812	
JP 2007502308	T	20070208	JP 2006-523673	20040812	
IN 2006DN00703	A	20070824	IN 2006-DN703	20060213	
NO 2006000718	A	20060301	NO 2006-718	20060214	
US 2006281666	A1	2006214	US 2006-568380	20060214	
MX 2006PA01775	A	20060517	MX 2006-PA1775	20060215	
PRAI US 2003-495580P	P	20040815			
US 2004-576416P	P	20040528			
WO 2004-GB3473	W	20040812			
OS CASREACT 142:261391; MARPAT 142:261391					
G1					



AB Title compds. I [R1, R2 = H, (un)substituted alkyl, (un)substituted heterocycl], with proviso that R1 and R2 are not both H; or R1 and R2 and the N to which they are attached in combination form an optionally substituted heterocycl; R4 = H, OH, (un)substituted carbocycl, etc.; R5 = H, (un)substituted carbocycl, (un)substituted alkyl and their pharmaceutically acceptable salts were prepared. For example, amidation of compound II with (CH₃)₂Al-3-BOC-(S)-3-aminopiperidine, e.g., in-situ prepared by reaction of (S)-3-aminopiperidine-1-carboxylic acid tert-Bu ester with (CH₃)₂Al, followed by acidic deprotection afforded compound I [NR1R2 = (S)-piperidin-3-ylamino; R4 = H; OR5 = 4-MeO₂HCl] in 57% overall yield. In CHK 1 (checkpoint kinase 1) inhibition assays, the IC₅₀ value of compound I [NR1R2 = piperidin-3-ylamino; R4 = H; OR5 = 4-Et₂NCH₂CH₂OEt-CF₃CO₂H] was 10 nM. Compds. I are claimed useful for the treatment of cancer, infection.


IT 845887-80-1P 845887-93-2P 845888-00-3P

845888-22-4P 845888-36-0P 845888-40-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (preparation of thiophene compds. as CHK1 inhibitors for treatment of cancer, infection)


RN 845887-80-1 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-(2-aminoethyl)-5-(4-methoxyphenyl)- (CA INDEX NAME)



RN 845887-99-2 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-(2-

RN 845888-40-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-(2-methoxyethyl)-5-(4-methoxyphenyl)- (CA INDEX NAME)



**RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT**

L1 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005;101567 CAPLUS Full-text

DN 142;329317

TI Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of I κ B kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced cell proliferation

AU Podolin, Patricia L.; Callahan, James F.; Bolognese, Brian J.; Li, Yue H.; Carlson, Karen; Davis, T. Gregg; Mellor, Geoff W.; Evans, Christopher; Roskak, Amy K.

CS Respiratory and Inflammation Center of Excellence for Drug Discovery, GlaxoSmithKline, King of Prussia, PA, USA

SO Journal of Pharmacology and Experimental Therapeutics (2005), 312(1), 373-381

CODEN: JPETAB; **ISSN:** 0022-3565


PB American Society for Pharmacology and Experimental Therapeutics

DT Journal

LA English


AB Demonstration that I κ B kinase 2 (IKK-2) plays a pivotal role in the nuclear factor- κ B-regulated production of proinflammatory mols. by stimuli such as tumor necrosis factor (TNF)- α and interleukin (IL)-1 suggests that inhibition of IKK-2 may be beneficial in the treatment of rheumatoid arthritis. In the present study, we demonstrate that a novel, potent (IC₅₀ = 17.9 nM), and selective inhibitor of human IKK-2, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide (TPCA-1), inhibits lipopolysaccharide-induced human monocyte production of TNF- α , IL-6, and IL-1 β , with an IC₅₀ = 170 to 320 nM. Prophylactic administration of TPCA-1 at 3, 10, or 20 mg/kg, i.p., b.i.d., resulted in a dose-dependent reduction in the severity of murine collagen-induced arthritis (CIA). The significantly reduced disease severity and delay of disease onset resulting from administration of TPCA-1 at 10 mg/kg, i.p., b.i.d., were comparable to the effects of the antirheumatic drug, etanercept, when administered prophylactically at 4 mg/kg, i.p., every other day. Nuclear localization of p65, as well as levels of IL-1 β , IL-6, TNF- α , and interferon- γ , were significantly reduced in the paw tissue of TPCA-1- and etanercept-treated mice. In addition, administration of TPCA-1 in vivo resulted in significantly decreased collagen-induced T cell proliferation ex vivo. Therapeutic administration of TPCA-1 at 20 mg/kg, but not at 3 or 10 mg/kg, i.p., b.i.d., significantly reduced the severity of CIA, as did etanercept administration at 12.5 mg/kg, i.p., every other day. These results

(dimethylamino)ethyl)-5-(4-methoxyphenyl)- (CA INDEX NAME)




RN 845888-00-8 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-[2-(diethylamino)ethyl]-5-(4-methoxyphenyl)- (CA INDEX NAME)




RN 845888-22-4 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-(2-hydroxyethyl)-5-(4-hydroxyphenyl)- (CA INDEX NAME)



RN 845888-36-0 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(3-methoxypropyl)- (CA INDEX NAME)



suggest that reduction of proinflammatory mediators and inhibition of antigen-induced T cell proliferation are mechanisms underlying the attenuation of CIA by the IKK-2 inhibitor, TPCA-1.


IT 567475-17-4

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiarthritic activity of small mol. inhibitor of I κ B kinase 2, TPCA-1, via reduction of proinflammatory cytokines and antigen-induced T cell proliferation)

RN 507475-17-4 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)



**RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT**

L1 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004;606462 CAPLUS Full-text

DN 141;157027

TI Preparation of thiophenecarboxamides as IKK-2 inhibitors for the treatment of inflammatory diseases.

IN Paull, Alan Wellington; Johnstone, Craig; Morley, Andrew David; Poyser, Jeffrey Philip

PA AstraZeneca Ab, Sigtuna, AstraZeneca UK Limited

SO PCT Int. Appl., 59 pp.


CODEN: PIXXD2

DT


LA English

FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	TYPE
PI WO 2004063186	A1	20040729	WO 2004-GB96	20040113
W: AE, AG, AL, AM, AT, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MQ, MN, MM, MX, MZ				
EP 1583755	A1	20051012	EP 2004-701627	20040113
R: AT, BE, CH, DE, DK, ES, FR, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006516273	T	20060629	JP 2006-500200	20040113
US 2006058522	A1	20060316	US 2005-542326	20050713
PRAI SE 2003-92	A	20030115		
WO 2004-GB96	W	20040113		
OS MARPAT 141:157027				
GI				





RN 728947-84-0 CAPLUS
CN 3-Thiophene carboxamide, 2-((aminocarbonyl)amino)-5-[4-((2-hydroxy-1-methylethyl)amino)methyl]phenyl - (CA INDEX NAME)



RN 728947-91-9 CAPLUS
CN 3-Thiophene carboxamide, 2-((aminocarbonyl)amino)-5-[4-((5-cyanopentyl)amino)methyl]phenyl - (CA INDEX NAME)



RN 728947-93-1 CAPLUS
CN 3-Thiophene carboxamide, 2-((aminocarbonyl)amino)-5-[4-((2-methylpropyl)amino)methyl]phenyl, mono(trifluoroacetate) (9CI) (CA INDEX NAME)




CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 728947-97-5 CAPLUS
CN 3-Thiophene carboxamide, 2-((aminocarbonyl)amino)-5-[4-((2-hydroxyethyl)amino)methyl]phenyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1
CRN 728947-96-4
CMF C15 H18 N4 O3 S




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 728947-98-6 CAPLUS
CN 3-Thiophene carboxamide, 2-((aminocarbonyl)amino)-5-[4-((2-methoxy-2-methylpropyl)amino)methyl]phenyl - (CA INDEX NAME)




RN 728948-03-6 CAPLUS
CN 2-Thiophene carboxamide, 3-((aminocarbonyl)amino)-5-[4-((ethyl(2-methoxyethyl)amino)methyl]phenyl - (CA INDEX NAME)




RN 728948-04-7 CAPLUS
CN 2-Thiophene carboxamide, 3-((aminocarbonyl)amino)-5-[4-((2-methoxyethyl)methylamino)methyl]phenyl - (CA INDEX NAME)




RN 728948-06-9 CAPLUS
CN 2-Thiophene carboxamide, 3-((aminocarbonyl)amino)-5-[4-((2-cyanoethyl)methylamino)methyl]phenyl - (CA INDEX NAME)




RN 728948-07-0 CAPLUS
CN 2-Thiophene carboxamide, 3-((aminocarbonyl)amino)-5-[4-((2-methoxyethyl)amino)methyl]phenyl - (CA INDEX NAME)




RN 728948-12-7 CAPLUS
CN 2-Thiophene carboxamide, 3-((aminocarbonyl)amino)-5-[4-((2-hydroxyethyl)methylamino)methyl]phenyl - (CA INDEX NAME)




RN 728948-13-8 CAPLUS
CN 2-Thiophene carboxamide, 3-((aminocarbonyl)amino)-5-[4-((2-methoxyethyl)methylamino)methyl]phenyl - (CA INDEX NAME)




RN 728948-17-2 CAPLUS
CN 2-Thiophene carboxamide, 3-((aminocarbonyl)amino)-5-[4-((2-methoxy-2-methylpropyl)methylamino)methyl]phenyl - (CA INDEX NAME)




RN 728948-18-3 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(3-methoxypropyl)amino]methyl]phenyl- (CA INDEX NAME)



RN 728948-19-4 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(diethylamino)methyl]phenyl- (CA INDEX NAME)




RN 728948-20-7 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(2-cyanoethyl)methylamino]methyl]phenyl- (CA INDEX NAME)




RN 728948-22-9 CAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(2-hydroxyethyl)methylamino]methyl]phenyl- (CA INDEX NAME)



RN 728948-24-1 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(bis(2-hydroxyethyl)methylamino)methyl]phenyl- (CA INDEX NAME)




IT 494773-25-0F, 2-[(Aminocarbonyl)amino]-5-(4-formylphenyl)thiophene-3-carboxamide 738948-32-0F
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiophenylcarboxamides as IKK-2 inhibitors for the treatment of inflammatory diseases.)
RN 494773-25-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-formylphenyl)- (CA INDEX NAME)




ANSWER 13 OF 20. CAPLUS COPYRIGHT 2007 ACS on STN
2004:362566 CAPLUS Full-text


DN 141:9900
TI Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors
AU Baxter, Andrew; Brough, Steve; Cooper, Anne; Floettmann, Eike; Foster, Steve; Harding, Christine; Kettle, Jason; McNally, Tom; Martin, Craig; Hobbs, Michelle; Needham, Maurice; Newham, Pete; Paine, Stuart; St-Galley, Steve; Salter, Sylvia; Unit, John; Xue, Yafang
CS AstraZeneca R&D Charnwood, Loughborough, LE11 5RH, UK
SO Biorganic & Medicinal Chemistry Letters (2004), 14(11), 2817-2822
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
CI




RN 354810-95-0 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)- (CA INDEX NAME)




RN 354811-01-1 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(3-hydroxyphenyl)- (CA INDEX NAME)




RN 354811-04-4 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(2-chlorophenyl)- (CA INDEX NAME)



RN 354811-06-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(2-methoxyphenyl)- (CA INDEX NAME)
















AB A hit-to-lead optimization program was carried out on the thiophenecarboxamide high throughput screening hits 1 and 2 resulting in the discovery of the potent and orally bioavailable IKK-2 inhibitor (I).
IT J54810-63-0 354810-05-0 354811-01-1
354811-01-1 354811-06-6 354811-09-0
354811-09-0 718620-76-9 718620-77-0
718620-77-0 718620-79-2 718620-81-6
RL: PAC (Pharmacological activity); BIOL (Biological study)
(high throughput screening of potent, orally active, thiophenecarboxamide IKK-2 inhibitors)
RN 354810-83-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(3-chlorophenyl)- (CA INDEX NAME)




5-(4-Hydroxy-3-methoxyphenyl)-2-(3-methylureido)thiophene-3-carboxylic acid methylamide 507475-53-SP
 , 5-(4-Hydroxy-3-methoxyphenyl)-2-(3-methylureido)thiophene-3-carboxylic acid methylamide 507475-54-DF, 5-(4-Hydroxy-3-methoxyphenyl)-2-(3-methylureido)thiophene-3-carboxylic acid methylamide 507475-55-OP
 , 5-(3,4-Dimethoxyphenyl)-2-(3-methylureido)thiophene-3-carboxylic acid methylamide 507475-56-1F, 5-(3-Fluorophenyl)-2-ureidothiophene-3-carboxylic acid amide 507475-57-2F, 5-(3-Cyanophenyl)-2-ureidothiophene-3-carboxylic acid amide 507475-58-2F,
 5-(4-Ethylphenyl)-2-ureidothiophene-3-carboxylic acid amide 507475-59-4F, 5-(3-Methoxyphenyl)-2-ureidothiophene-3-carboxylic acid amide 507475-60-5F, 5-(3-Hydroxymethylphenyl)-2-ureidothiophene-3-carboxylic acid amide 507475-61-5P,
 5-(3,4-Dichlorophenyl)-2-ureidothiophene-3-carboxylic acid amide 507475-62-5P, 5-(3-Trifluoromethylphenyl)-2-ureidothiophene-3-carboxylic acid amide 507475-63-5P, 5-(3,4-Difluorophenyl)-2-ureidothiophene-3-carboxylic acid amide 507475-64-1F,
 [5-Phenyl-3-(1-ureidomethanoyl)thiophen-2-ylurea 507475-65-2F, 1-Methyl-3-(5-phenyl-3-(1-ureidomethanoyl)thiophen-2-ylurea 507475-67-4P, [5-(4-Fluorophenyl)-3-(1-ureidomethanoyl)thiophen-2-ylurea
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Uses)
 (drug candidate; preparation of 2-ureidothiophenes as angiogenesis and Chk1 kinase inhibitors for treating various forms of cancer and hyperproliferative disorders)


RN 106666-34-6 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(methylamino)carbonyl]amino-5-phenyl- (9CI) (CA INDEX NAME)


RN 354811-10-2 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-phenyl- (CA INDEX NAME)RN 354811-59-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)RN 412914-36-4 CAPLUS
CN 3-Thiophenecarboxamide, 5-(3-chlorophenyl)-2-[(methylamino)carbonyl]amino- (CA INDEX NAME)RN 412914-37-5 CAPLUS
CN 3-Thiophenecarboxamide, 5-(4-fluorophenyl)-2-[(methylamino)carbonyl]amino- (CA INDEX NAME)RN 412914-52-4 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(ethylamino)carbonyl]amino-5-phenyl- (CA INDEX NAME)RN 412914-54-6 CAPLUS
CN 3-Thiophenecarboxamide, 5-(2-fluorophenyl)-2-[(methylamino)carbonyl]amino- (CA INDEX NAME)RN 354811-67-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-chlorophenyl)- (CA INDEX NAME)RN 354811-68-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)RN 354812-11-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)- (CA INDEX NAME)RN 412914-57-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(methylamino)carbonyl]amino-5-(4-methylphenyl)- (CA INDEX NAME)RN 412914-58-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)RN 507475-17-4 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)RN 507475-20-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methylphenyl)- (CA INDEX NAME)




RN 507475-21-0 CAPLUS
CN 3-Thiophene carboxamide, 5-(4-chlorophenyl)-2-[(methylamino)carbonyl]amino - (CA INDEX NAME)




RN 507475-23-2 CAPLUS
CN 3-Thiophene carboxamide, 5-(4-fluorophenyl)-N-methyl-2-[(methylamino)carbonyl]amino - (CA INDEX NAME)




RN 507475-24-3 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-N-methyl - (CA INDEX NAME)




RN 507475-25-4 CAPLUS
CN 3-Thiophene carboxamide, N-methyl-2-[(methylamino)carbonyl]amino-5-phenyl - (CA INDEX NAME)




RN 507475-26-5 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-N-methyl-5-phenyl - (CA INDEX NAME)



RN 507475-29-8 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-5-(2-fluorophenyl) - (CA INDEX NAME)




RN 507475-35-6 CAPLUS
CN 3-Thiophene carboxamide, 5-(4-methoxyphenyl)-2-[(methylamino)carbonyl]amino - (CA INDEX NAME)




RN 507475-37-8 CAPLUS


CN 3-Thiophene carboxamide, 5-(4-cyanophenyl)-2-[(methylamino)carbonyl]amino - (CA INDEX NAME)




RN 507475-38-9 CAPLUS
CN 3-Thiophene carboxamide, 5-[4-(dimethylamino)phenyl]-2-[(methylamino)carbonyl]amino - (CA INDEX NAME)




RN 507475-39-0 CAPLUS
CN 3-Thiophene carboxamide, 5-(4-hydroxymethyl)phenyl-2-[(methylamino)carbonyl]amino - (CA INDEX NAME)




RN 507475-40-3 CAPLUS
CN 3-Thiophene carboxamide, 5-(3-fluorophenyl)-2-[(methylamino)carbonyl]amino - (CA INDEX NAME)




RN 507475-41-4 CAPLUS
CN 3-Thiophene carboxamide, 5-(3-aminophenyl)-2-[(methylamino)carbonyl]amino - (CA INDEX NAME)




RN 507475-43-6 CAPLUS
CN 3-Thiophene carboxamide, 5-(4-aminophenyl)-2-[(methylamino)carbonyl]amino - (CA INDEX NAME)




RN 507475-44-7 CAPLUS
CN 3-Thiophene carboxamide, 5-(3-hydroxyphenyl)-2-[(methylamino)carbonyl]amino - (CA INDEX NAME)




RN 507475-46-9 CAPLUS
CN 3-Thiophene carboxamide, 5-(3-acetylphenyl)-2-[(methylamino)carbonyl]amino - (CA INDEX NAME)




RN 507475-50-5 CAPLUS
 CN 3-Thiophenecarboxamide, N-methyl-2-[(methylamino)carbonyl]amino]-5-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 507475-51-6 CAPLUS
 CN 3-Thiophenecarboxamide, 5-(4-methoxyphenyl)-N-methyl-2-[(methylamino)carbonyl]amino]- (CA INDEX NAME)




RN 507475-52-7 CAPLUS
 CN 3-Thiophenecarboxamide, 5-(4-aminophenyl)-N-methyl-2-[(methylamino)carbonyl]amino]- (CA INDEX NAME)




RN 507475-53-8 CAPLUS
 CN 3-Thiophenecarboxamide, 5-(4-hydroxy-3-methoxyphenyl)-N-methyl-2-[(methylamino)carbonyl]amino]- (CA INDEX NAME)


10537697 55 of 87
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-cyanophenyl)- (CA INDEX NAME)




RN 507475-58-3 CAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-ethylphenyl)- (CA INDEX NAME)




RN 507475-59-4 CAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)- (CA INDEX NAME)




RN 507475-60-7 CAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-hydroxymethylphenyl)- (CA INDEX NAME)




RN 507475-54-9 CAPLUS
 CN 3-Thiophenecarboxamide, 5-[4-(hydroxymethyl)phenyl]-N-methyl-2-[(methylamino)carbonyl]amino]- (CA INDEX NAME)



RN 507475-55-0 CAPLUS
 CN 3-Thiophenecarboxamide, 5-(3,4-dimethoxyphenyl)-N-methyl-2-[(methylamino)carbonyl]amino]- (CA INDEX NAME)




RN 507475-56-1 CAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-fluorophenyl)- (CA INDEX NAME)




RN 507475-57-2 CAPLUS

10537697 56 of 87


RN 507475-61-8 CAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3,4-dichlorophenyl)- (CA INDEX NAME)




RN 507475-62-9 CAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)




RN 507475-63-0 CAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3,4-difluorophenyl)- (CA INDEX NAME)




RN 507475-64-1 CAPLUS
 CN 3-Thiophenecarboxamide, N-(aminocarbonyl)-2-[(aminocarbonyl)amino]-5-phenyl- (CA INDEX NAME)



RN 507475-65-2 CAPLUS
CN 3-Thiophene carboxamide, N-(aminocarbonyl)-2-[(methylamino)carbonyl]amino-5-phenyl- (CA INDEX NAME)



RN 507475-67-4 CAPLUS
CN 3-Thiophene carboxamide, N-(aminocarbonyl)-2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 15 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
2003:282401 CAPLUS Full-text

DN 138:304152

TI Preparation of 3-ureidothiophenes as angiogenesis and Chk1 kinase inhibitors for treating various forms of cancer and hyperproliferative disorders
IN Parrish, Cynthia A.; Callahan, James F.; Wan, Zehong; Burgess, Joelle L.; Stavenger, Robert A.; Holt, Dennis A.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 40 pp.


CODEN: PIXX02

DT Patent


LA English

FAN.CNT 1


PATENT NO. KIND DATE APPLICATION NO. DATE




RN 354810-95-0 CAPLUS
CN 2-Thiophene carboxamide, 3-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)- (CA INDEX NAME)



RN 507472-56-2 CAPLUS
CN 2-Thiophene carboxamide, 5-(4-methoxyphenyl)-3-[(methylamino)carbonyl]amino- (CA INDEX NAME)




RN 507472-64-2 CAPLUS
CN 2-Thiophene carboxamide, 5-(4-methoxyphenyl)-N-methyl-3-[(methylamino)carbonyl]amino- (CA INDEX NAME)



RN 507472-66-4 CAPLUS
CN 2-Thiophene carboxamide, 3-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-methyl- (CA INDEX NAME)


PI 2003028731 A1 20030410 WO 2002-US31901 20021004
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RN: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UC, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TU, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GM, ML, MR, NE, SN, TD, TG
AU 2002330247 A1 20030414 AU 2002-330247 20021004
PRAI US 2001-326971P P 20011004
WO 2002-US31901 W 20021004
OS MARPAT 138:304152
GI




AB Ureidothiophenes (shown as I, variables defined below, e.g. 5-phenyl-3-ureidothiophene-2-carboxylic acid Me ester) useful in the inhibition of angiogenesis and damage response kinases (no data) are provided. Although the methods of preparation are not claimed, 36 example preps. are included. For I: R₁ = H, Cl-2 alkyl, XH, XCH₃, Cl-2-alkyl-XH, Cl-2-alkyl-XCH₃, C(O)NH₂, C(O)NRH₂, and C(O)-Cl-2-alkyl-, -O-, S, and NH; R₂ = C(O)R₅, CO₂R₅, C(O)NRH₅, C(O)NRH₅(:NH)NR₆, C(O)NRH₅(O)R₅, C(O)NRH₅NR₆, SO₂R₅, S(O)R₅, SO₂R₅, and PO₂R₅R₆. R₃ is H or halogen; R₄ is aryl or heteroaryl; addnl. details are given in the claims.

IT 254810-86-9P, 5-(4-Fluorophenyl)-3-ureidothiophene-2-carboxylic acid amide 354810-95-0P, 5-(4-Methoxyphenyl)-3-ureidothiophene-2-carboxylic acid amide 507472-56-2P, 5-(4-Methoxyphenyl)-3-(3-methylureido)thiophene-2-carboxylic acid methylamide 507472-66-4P, 5-(4-Methoxyphenyl)-3-ureidothiophene-2-carboxylic acid methylamide 507472-71-1P, 5-(4-Aminophenyl)-3-(3-methylureido)thiophene-2-carboxylic acid methylamide 507472-71-1P, 5-(4-Methoxyphenyl)-3-(3-methylureido)thiophene-2-carboxylic acid methylamide (drug candidate; preparation of 3-ureidothiophenes as angiogenesis and Chk1 kinase inhibitors for treating various forms of cancer and hyperproliferative disorders)
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


RN 354810-86-9 CAPLUS
CN 2-Thiophene carboxamide, 3-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)




RN 507472-67-5 CAPLUS
CN 2-Thiophene carboxamide, 5-(3,4-dimethoxyphenyl)-N-methyl-3-[(methylamino)carbonyl]amino- (CA INDEX NAME)



RN 507472-71-1 CAPLUS
CN 2-Thiophene carboxamide, 5-(4-aminophenyl)-N-methyl-3-[(methylamino)carbonyl]amino- (CA INDEX NAME)



IT 507472-73-3P, 5-(4-Nitrophenyl)-3-(3-methylureido)thiophene-2-carboxylic acid methylamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3-ureidothiophenes as angiogenesis and Chk1 kinase inhibitors for treating various forms of cancer and hyperproliferative disorders)
RN 507472-73-3 CAPLUS
CN 2-Thiophene carboxamide, N-methyl-3-[(methylamino)carbonyl]amino]-5-(4-nitrophenyl)- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
2003:97411 CAPLUS Full-text
DN 138:137162
TI Preparation of ureido-carboxamido thiophenes as inhibitors of IKK2 kinase
IN Faull, Alan; Johnstone, Craig; Morley, Andrew; Poyser, Jeffrey Philip
PA Astrazeneca A.B., Swed.
SO PCT Int. Appl., 180 pp.
CODEN: PIXXD2


DT Patent

LA English

PAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003010158	A1	20030206	WO 2002-SE1403	20020719
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, ES, FI, FR, GB, GR, IS, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NB, SN, TD, TG				
CA 2454703	A1	20030206	CA 2002-2454703	20020719
AU 2003355245	A1	20030217	AU 2002-355245	20020719
EP 1421074	A1	20040526	EP 2002-751935	20020719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011473	A	20041026	BR 2002-1473	20020719
CN 1541214	A	20041027	CN 2002-815836	20020719
JP 200503372	T	20050203	JP 2003-515517	20020719
NZ 530750	A	20050826	NZ 2002-530750	20020719
US 2004242573	A1	20041202	US 2004-484569	20040122
US 7125896	B2	20061024		
ZA 2004000492	A	20050422	ZA 2004-492	20040122
NO 2004000313	A	20040325	NO 2004-313	20040123
MO 2004PA00756	A	20040420	MO 2004-PA756	20040123
HK 1071129	A1	20061229	HK 2005-103629	20050427
US 2007015819	A1	20070118	US 2006-516225	20060906
PRAI SE 2001-2616	A	20010725		
WO 2002-SE1403	W	20020719		
US 2004-484569	A3	20040122		
OS MARPAT 138:137162				

GI




AB Title compds. I [R1 = NH2, (un)substituted methyl; X = O, S; R2 = H, halo, CN, NO2, amino, carboxamido, carboxy, etc.; A = Ph, 5-7-membered (un)substituted heteroarom. ring; n = 1-2; R3 = W-Y-Z; W = O, SOO-2; amino, CH2(O), bond, Y = (CH2)2-2-T-(CH2)-2; T = O, CO, alkyl; Z = Ph, 5-6-membered (un)substituted heteroarom. ring, etc.; with specific exceptions] are prepared. For instance, 55° are reacted to give 2-Amino-4-methyl-5-(1,1'-biphenyl-4-yl)-3-thiophenecarboxamide. This intermediate is treated with trichloroacetyl isocyanate and ammonia in MeOH to give example compound II. Compds. of the invention have IC50 < 10 μM for IKK2 Kinase. I are useful for the treatment of inflammatory diseases.

IT 494772-53-3P, 2-[(Aminocarbonyl)amino]-5-[4-[2-(2-methoxyethoxy)ethoxy]phenyl]-3-thiophenecarboxamide 494772-74-6P, 2-[(Aminocarbonyl)amino]-5-[4-[2-(2-methoxyethoxy)ethoxy]-3-methylphenyl]-3-thiophenecarboxamide 494772-76-6P,

2-[(Aminocarbonyl)amino]-5-[3-chloro-4-[2-(2-methoxyethoxy)ethoxy]phenyl]-3-thiophenecarboxamide 494772-55-0P, 2-[(Aminocarbonyl)amino]-5-[2-(2-hydroxyethoxy)phenyl]thiophene-3-carboxamide


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

RN 494772-63-3 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(2-methoxyethoxy)ethoxy]phenyl]- (CA INDEX NAME)




RN 494772-74-6 CAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(2-methoxyethoxy)ethoxy]-3-methylphenyl]- (CA INDEX NAME)



RN 494772-76-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(2-hydroxyethoxy)phenyl]- (CA INDEX NAME)




RN 494773-59-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-(2-hydroxyethoxy)phenyl]- (CA INDEX NAME)




IT 494772-73-1P, 2-[(Aminocarbonyl)amino]-5-(2-formylphenyl)-3-thiophenecarboxamide 494773-25-0P, 2-[(Aminocarbonyl)amino]-5-(4-formylphenyl)thiophene-3-carboxamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (preparation of ureido-carboxamido thiophenes as inhibitors of IKK2 kinase)

RN 494772-79-1 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2-formylphenyl)- (CA INDEX NAME)



RN 494773-25-0 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-formylphenyl)- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
2002:293385 CAPLUS Full-text
DN 136:325411

TI Preparation of 2-aminothiophene-3-carboxamides as NF-κB inhibitors
IN Callahan, James F/T/RØRNMARK, Amy K.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DT Patent

LA English

PAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002030353	A2	20020418	WO 2001-US31866	20011012
WO 2002030353	A3	20020627		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, AT, BE, BG, CH, CY, DE, DK, ES, FI, FR, GB, GR, IS, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002011663 A5 200204224 AU 2002-11663 20011012
EP 1324759 A2 20030709 EP 2001-979731 20011012
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, RO, MK, CY, AL, TR
JP 2004523476 T 20040805 JP 2002-533800 20011012
US 2004024047 A1 20040205 US 2009-39875 20030410
US 2006030596 A1 20060209 US 2005-237232 20050928

ADN
OZ

10537697
 PRAI UO 2000-239759P P 20001012
 MO 2001-US31866 W 20011012
 US 2003-39847 B1 20030410
 OS MARPAT 136:J25411
 GI



AB The title compds. [I; R1 = NR5R6; R2 = CONH2, SO2NH2; R3 = H, halo; R4 = aryl, heteroaryl; R5 = H, alkyl; R6 = H, Coalkyl, SO2alkyl, etc.], useful as inhibitors of IKK- β phosphorylation of I κ B, were prepared. Thus, treating (4-fluorophenyl)ethanol with PCC in CH2Cl2 followed by reacting the resulting (4-fluorophenyl)acetaldehyde with sulfur and 2-cyanoacetamide in the presence of Et3N in DMF afforded 2-amino-5-(4-fluorophenyl)thiophene-3-carboxamide.

IT 106666-34-6P 106666-36-8P 412914-52-4P 412914-54-6P


412914-57-9P 412914-58-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 2-aminothiophene-3-carboxamides as NF- κ B inhibitors)

RN 106666-34-6 CAPLUS

CN 3-Thiophene carboxamide, 2-[(methylamino)carbonyl]amino-5-phenyl- (9CI) (CA INDEX NAME)




RN 106666-36-8 CAPLUS
 CN 3-Thiophene carboxamide, 2-[(1-methylethyl)amino]carbonyl]amino-5-phenyl- (9CI) (CA INDEX NAME)




10537697 67 of 87

RN 412914-57-9 CAPLUS
 CN 3-Thiophene carboxamide, 2-[(methylamino)carbonyl]amino-5-(4-methylphenyl)- (CA INDEX NAME)



RN 412914-58-0 CAPLUS
 CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-5-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)



L10 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2007 ACS ON STN

AN 2001-597977 CAPLUS Full-text

DW 135-180698

TI Preparation of thiophene carboxamides as inhibitors of the enzyme IKK-2
 IN Baxter, Andrew; Brough, Stephen; Faull, Alan; Johnstone, Craig; McInally, Thomas

PA Astrazeneca AB, Swed.
 SO PCT Int. Appl., 85 pp.

CODEN: PIXDZ2

DT Patent


LA English

FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI NO 2001058890	A1	20010816	WO 2001-SE248	20010207
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MR, MN, MM, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TZ, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DB, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

10537697 68 of 87


RN 412914-36-4 CAPLUS
 CN 3-Thiophene carboxamide, 5-(3-chlorophenyl)-2-[(methylamino)carbonyl]amino- (CA INDEX NAME)




RN 412914-37-5 CAPLUS
 CN 3-Thiophene carboxamide, 5-(4-fluorophenyl)-2-[(methylamino)carbonyl]amino- (CA INDEX NAME)



RN 412914-52-4 CAPLUS
 CN 3-Thiophene carboxamide, 2-[(ethylamino)carbonyl]amino-5-phenyl- (CA INDEX NAME)



RN 412914-54-6 CAPLUS
 CN 3-Thiophene carboxamide, 5-(2-fluorophenyl)-2-[(methylamino)carbonyl]amino- (CA INDEX NAME)



10537697 68 of 87

CA 2396824 A1 20010816 CP 2001-2396824 20010207
 EP 1261600 A1 20021204 EP 2001-902951 20010207
 EP 1261600 B1 20040506

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, PI, RO, MK, CY, AL, TR
 BR 2001008143 A 20030121 BE 2001-8143 20010207
 JP 2003522766 T 20030729 JP 2001-558440 20010207
 AT 266019 T 20040515 AT 2001-902951 20010207
 NZ 519947 A 20040528 NZ 2001-519947 20010207
 PT 1261600 T 20040831 PT 2001-902951 20010207
 ES 2218376 T3 20041116 ES 2001-1902951 20010207
 AU 781047 B2 20050505 AU 2001-30705 20010207
 US 2002107252 A1 20020808 US 2002-868884 20020205
 ZA 2002005300 A 20031002 ZA 2002-5100 20020207
 NO 2002001786 A 20020923 NO 2002-1786 20020809
 MX 2002PA07734 A 20021011 MX 2002-PA7734 20020809
 PRAI GB 2000-3154 A 20000212
 NO 2001-SE248 W 20010207

OS MARPAT 135:180698

GI




AB The title compds. [I; R1 = 5-membered heteroarom. ring containing 1-2 heteroatoms selected from O, N or S; R1 = (un)substituted Ph, 5-7 membered heteroarom. ring containing 1-3 heteroatoms selected from O, N or S; R2 = H, halo, CN, etc.; X = O, S], useful in the treatment or prophylaxis of inflammatory disease, were prepared. Thus, refluxing 3-amino-5-phenyl-2-thiophene carboxamide with trimethylsilyl isocyanate in DMF/CH2Cl2 afforded II.

IT 354811-01-1P 354811-06-6P 354811-31-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(preparation of thiophene carboxamides as inhibitors of the enzyme IKK-2)

RN 354811-01-1 CAPLUS
 CN 2-Thiophene carboxamide, 3-[(aminocarbonyl)amino]-5-(3-hydroxyphenyl)- (CA INDEX NAME)




RN 354811-06-6 CAPLUS
 CN 2-Thiophene carboxamide, 3-[(aminocarbonyl)amino]-5-(2-methoxyphenyl)- (CA INDEX NAME)

INDEX NAME)




RN 354811-31-7 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-4-methyl- (CA INDEX NAME)




IT 254810-80-3P 254810-83-6P 254810-86-5P
154810-83-1P 254810-90-5P 254810-95-0P
254811-04-1P 254811-07-7F 254811-08-8P
254811-09-5P 254811-10-3P 254811-11-5P
254811-15-7P 254811-19-1P 254811-27-1P
254811-24-3P 254811-29-3P 254811-30-6P
254811-32-5P 254811-32-9P 254811-34-0P
254811-35-1P 254811-36-2P 254811-37-3P
254811-38-4P 254811-39-5P 254811-40-6P
254811-41-9P 254811-42-0P 254811-48-6P
254811-49-7P 254811-50-0P 254811-52-2P
254811-54-4P 254811-56-6P 254811-58-8P
254811-59-9P 254811-60-1P 254811-66-6P
254811-67-9P 254811-68-0P 254811-80-3P
254811-91-6P

RL BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PREP (Preparation); USES (Uses) (preparation of thiophenecarboxamides as inhibitors of the enzyme IKK-2)
RN 354810-80-3 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-phenyl- (CA INDEX NAME)




10537697 71 of 87


CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)- (CA INDEX NAME)




RN 354811-04-4 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(2-chlorophenyl)- (CA INDEX NAME)



RN 354811-07-7 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[2-(2-dimethylamino)ethoxy]phenyl- (CA INDEX NAME)




RN 354811-08-8 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-(2-dimethylamino)ethoxy]phenyl- (CA INDEX NAME)




RN 354811-09-9 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)- (CA INDEX NAME)


RN 354810-83-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(3-chlorophenyl)- (CA INDEX NAME)




RN 354810-86-9 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)



RN 354810-88-1 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-chlorophenyl)- (CA INDEX NAME)




RN 354810-90-5 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-(2-methylpropyl)phenyl)- (CA INDEX NAME)




RN 354810-95-0 CAPLUS


10537697 72 of 87




RN 354811-10-2 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-phenyl- (CA INDEX NAME)




RN 354811-14-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-(3-dimethylamino)propoxy]phenyl- (CA INDEX NAME)




RN 354811-15-7 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[3-(2-dimethylamino)ethoxy]phenyl- (CA INDEX NAME)




RN 354811-19-1 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[3-(3-dimethylamino)propoxy]phenyl- (CA INDEX NAME)




RN 354811-27-1 CAPLUS
CN 2-Thiophene carboxamide, 3-[(aminocarbonyl)amino]-5-[2-(3-dimethylamino)propoxy]- (CA INDEX NAME)




RN 354811-28-2 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-5-(4-chlorophenyl)-4-methyl- (CA INDEX NAME)




RN 354811-29-3 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-(4-methylphenyl)- (CA INDEX NAME)




RN 354811-30-6 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-4-ethyl-5-phenyl- (CA INDEX NAME)




RN 354811-32-8 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-4-methyl- (CA INDEX NAME)




RN 354811-33-9 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-5-(3-fluorophenyl)-4-methyl- (CA INDEX NAME)




RN 354811-34-0 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)-4-methyl- (CA INDEX NAME)




RN 354811-35-1 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-5-(3-chloro-4-methoxyphenyl)-4-methyl- (CA INDEX NAME)




RN 354811-39-5 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-5-(3,5-dimethoxyphenyl)-4-methyl- (CA INDEX NAME)




RN 354811-40-8 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-5-(2,3-dimethoxyphenyl)-4-methyl- (CA INDEX NAME)




RN 354811-41-9 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-(4-(1-methylethyl)phenyl)- (CA INDEX NAME)




RN 354811-42-0 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 354811-38-4 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxy-3-methylphenyl)-4-methyl- (CA INDEX NAME)




RN 354811-42-0 CAPLUS
CN 3-Thiophene carboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)







RN 354811-48-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3,4-dichlorophenyl)-4-methyl- (CA INDEX NAME)



RN 354811-49-7 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-cyanophenyl)-4-methyl- (CA INDEX NAME)




RN 354811-50-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)-4-methyl- (CA INDEX NAME)




RN 354811-52-2 CAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(2-diethylamino)ethoxy]phenyl-4-methyl- (CA INDEX NAME)




RN 354811-54-4 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-phenyl-4-(trifluoromethyl)- (CA INDEX NAME)




RN 354811-56-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-phenyl- (CA INDEX NAME)




RN 354811-58-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)- (CA INDEX NAME)




CN 354811-59-9 CAPLUS
3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 354811-60-2 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2,4-difluorophenyl)- (CA INDEX NAME)




RN 354811-66-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)- (CA INDEX NAME)




RN 354811-67-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-chlorophenyl)- (CA INDEX NAME)



CN 354811-82-8 CAPLUS
3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(dimethylamino)ethoxy]phenyl- (CA INDEX NAME)




CN 354811-83-9 CAPLUS
3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(2-diethylamino)ethoxy]phenyl- (CA INDEX NAME)




IT 354811-95-3P 354811-96-4P 354812-11-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiophenecarboxamides as inhibitors of the enzyme IKK-2)


RN 354811-95-3 CAPLUS
2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(2-hydroxyphenyl)- (CA INDEX NAME)



RN 354811-96-4 CAPLUS
CN 2-Thiophencarboxamide, 3-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)- (CA INDEX NAME)



RN 354812-11-6 CAPLUS
CN 3-Thiophencarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)- (CA INDEX NAME)




RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1987:423224 CAPLUS Full-text
DN 107:23224
TI Thioureas and isoureas and their preparation and use as growth promoters for animals
IN Hallenbach, Werner; Lindel, Hans; Berschauer, Friedrich; Scheer, Martin;
De Jong, Arno
PA Bayer A.-G., Fed. Rep. Ger.
SO Ger. Offen., '79 pp.
CODEN: EPXXDM
DT Patent
LA German
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3529247	A1	19861120	DE 1985-3529247	19850816
EP 202538	A1	19861126	EP 1986-106209	19860506
EP 202538	B1	19881228		

R:	AT, BE, CH, DE, FR, GB, IT, LI, NL, SE	AT 39404	T 19890115	AT 1986-106209	19860506
AU	19865217	A	19861120	AT 1986-57217	19860507
JP	61268678	A	19861128	JP 1986-109713	19860515
DE	8602300	A	19861118	DE 1986-2300	19860516
BR	8602224	A	19870113	BR 1986-2224	19860516
ZA	8603645	A	19870128	ZA 1986-3645	19860516
HU	41244	A2	19870428	HU 1986-2086	19860516
ES	555052	A1	19880216	ES 1986-555052	19860516
CS	258481	B2	19880816	CS 1986-3569	19860516
PT	8602201	A	19861128	PT 1986-2201	19860526
PRAI	DE 1985-3517706	A1	19850517		
DE	1985-3529247	A	19850816		
EP	1986-106209	A	19860506		
OS	CASREACT 107:23224				
GI					



AB Title compds. I (A = NR4CONR5R6, NR4C(OR5):NR6, R1, R2 = H, halo, NO2, CN, (halo)alkoxy, (halo)alkylthio, alkoxalkyl, (un)substituted acyl, aroyl, alkyl, aryl; R1R2 complete a(n) (un)substituted carbocyclic or heterocyclic ring, optionally with a carbonyl function; R3 = CN, CO2R7, CONR8R9, COR10; R4 = H, alkyl; R5, R6 = H, (un)substituted alkyl, cycloalkyl, alkenyl, aryl, heteroaryl; R7 = H, (un)substituted alkyl, cycloalkyl, alkenyl, aryl; R8 = H, alkyl, cycloalkyl; R9, R10 = (un)substituted alkyl or aryl), useful as growth promoters for animals, were prepared by 3 methods. 2-Aminotetrahydrobenzothiophene-3-carboxamide and MeNCO in CHCl3 were refluxed 24 h to give 95% II. Rats fed with 10 ppm II mixed in their feed gained 14% more weight than the controls.

IT 106666-34-6P 106666-36-8P 106666-50-6P


106666-51-7P 106666-52-9P 106666-20-9P

103254-55-8P 103254-56-9P

RL P (Synthetic preparation); PREP (Preparation)
(preparation of, as animal growth promoter)


RN 106666-34-6 CAPLUS

CN 3-Thiophencarboxamide, 2-[(methylamino)carbonyl]amino]-5-phenyl- (9CI)
(CA INDEX NAME)




RN 106666-36-8 CAPLUS


CN 3-Thiophencarboxamide, 2-[(1-methylethyl)amino]carbonyl]amino)-5-phenyl- (9CI) (CA INDEX NAME)




RN 106666-50-6 CAPLUS
CN 3-Thiophencarboxamide, 4-methyl-2-[(methylamino)carbonyl]amino)-5-phenyl- (9CI) (CA INDEX NAME)




RN 106666-51-7 CAPLUS
CN 3-Thiophencarboxamide, 4-methyl-2-[(2-methylpropyl)amino]carbonyl]amino-5-phenyl- (9CI) (CA INDEX NAME)




RN 106666-52-8 CAPLUS
CN 3-Thiophencarboxamide, 2-[(butylamino)carbonyl]amino)-4-methyl-5-phenyl- (9CI) (CA INDEX NAME)




RN 106666-20-8 CAPLUS
CN 3-Thiophencarboxamide, 4-methyl-2-[(1-methylethyl)amino]carbonyl]amino-5-phenyl- (9CI) (CA INDEX NAME)



RN 108354-55-8 CAPLUS
CN 3-Thiophencarboxamide, 4-methyl-2-[(1-methylpropyl)amino]carbonyl]amino-5-phenyl- (9CI) (CA INDEX NAME)



RN 108354-56-9 CAPLUS
CN 3-Thiophencarboxamide, 2-[(1,1-dimethylethyl)amino]carbonyl]amino)-4-methyl-5-phenyl- (9CI) (CA INDEX NAME)



L10 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1987:63475 CAPLUS Full-text

DN 106183475

TI Productivity-increasing agents for livestock

IN Hallenbach, Werner; Lindel, Hans; Berschauer, Friedrich; Scheer, Martin;

De Jong, Arno

PA Bayer A.-G., Fed. Rep. Ger.

SO Eur. Pat. Appl., '80 pp.

CODEN: EPXXDM

DT Patent

LA German

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 202538	A1	19861126	EP 1986-106209	19860506
EP 202538	B1	19881228		
R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
DE 3529247	A1	19861120	DE 1985-3529247	19850816
AT 39404	T	19890115	AT 1986-106209	19860506
PRAI DE 1985-3517706	A	19850517		
DE 1985-3529247	A	19850816		
EP 1986-106209	A	19860506		
OS MARPAT 106:83475				
GI				



AB Productivity-increasing agents for livestock comprise thienureas or thiénylisoureas derivs. I (A = NH₂, NCO, NR₄C(OR₅)NR₆, R₁, R₂ = H, halogen, nitro, CN, (un)substituted alkyl, aryl, etc.; R₃ = CN, COOR₇, CONR₈R₉, COR₁₀; R₄ = H, alkyl; R₅, R₆ = H, substituted alkyl, cycloalkyl, alkenyl, aryl, heteroaryl; R₇ = H, substituted alkyl, cycloalkyl, alkenyl, aryl; R₈ = H, alkyl, cycloalkyl; R₉ = H, substituted alkyl or aryl; R₁₀ = substituted alkyl or aryl). Thus, 21 thienureas and thiénylisoureas compds. were prepared N-Butyl-N'-[3-methoxycarbonyltetrahydrobenzothien-2-yl]urea, given to rats at 25 ppm. in their feed for 13 days increased weight gain by 13% over that of control rats.


IT 106666-34-6P 106666-36-8P 106666-50-6P

106666-51-7P 106666-52-8P 106666-20-8P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study); PREP (Preparation); USES (Uses); (preparation of, as livestock productivity-increasing agent)


RN 106666-34-6 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(methylamino)carbonyl]amino-5-phenyl- (9CI) (CA INDEX NAME)




RN 106666-36-8 CAPLUS


CN 3-Thiophenecarboxamide, 2-[(1-methylethyl)amino]carbonyl]amino-5-phenyl- (9CI) (CA INDEX NAME)




RN 106666-50-6 CAPLUS
CN 3-Thiophenecarboxamide, 4-methyl-2-[(methylamino)carbonyl]amino-5-phenyl- (9CI) (CA INDEX NAME)




RN 106666-51-7 CAPLUS
CN 3-Thiophenecarboxamide, 4-methyl-2-[(2-methylpropyl)amino]carbonyl]amino-5-phenyl- (9CI) (CA INDEX NAME)



RN 106666-52-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(butylamino)carbonyl]amino-4-methyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 106686-20-8 CAPLUS
CN 3-Thiophenecarboxamide, 4-methyl-2-[(1-methylethyl)amino]carbonyl]amino-5-phenyl- (9CI) (CA INDEX NAME)



>> d cost
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
CONNECT CHARGES	0.41	2.92
NETWORK CHARGES	0.06	0.48
SEARCH CHARGES	0.00	180.62
DISPLAY CHARGES	108.23	108.23
FULL ESTIMATED COST	108.70	292.25

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-16.38	-16.38

IN FILE 'CAPLUS' AT 11:01:25 ON 20 NOV 2007

```
>> log hold
COST IN U.S. DOLLARS
SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 108.70 292.25
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE -16.38 -16.38
```

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:01:31 ON 20 NOV 2007